| Drug ID: | Drug182 |
|---|---|
| Drug Name: | Ferric carboxymaltose |
| CID: | 139266768 |
| DrugBank ID: | DB08917 |
| Modality: | Small Molecule |
| Groups: | approved |
| US Approved: | YES |
| Other Approved: | YES |
| Identifier: | NCT02517151, , NCT04587141, , NCT00810030 |
| Molecular Formula: | C24H44FeO25- |
| Molecular Weight: | 788.4 g/mol |
| Isomeric SMILES: | C(C1C(C(C(C(O1)OC2C(OC(C(C2O)O)OC3C(OC(C(C3O)O)OC(C(CO)O)C(C(C(=O)[O-])O)O)CO)CO)O)O)O)O.O.[OH-].[O-2].[Fe+3] |
| Synonyms: | Ferric carboxymaltose; 9007-72-1; Injectafer; Injectafer;Iron Dextri-Maltose; BCP30646 |
| Phase 0: | 0 |
| Phase 1: | 7 |
| Phase 2: | 18 |
| Phase 3: | 51 |
| Phase 4: | 59 |
| Description: | Ferric Carboxymaltose is an iron replacement product and chemically, an iron carbohydrate complex. FDA approved on July 25, 2013. |
Molecular Structure
Knowledge Graph
| dtID | CID | Compound Name | Gene ID | Gene Name | Species | PubMed IDs | Action |
|---|---|---|---|---|---|---|---|
| No data available | |||||||
- No data available
Phase Distribution
Phase Description
- Phase 0: Exploratory trials to assess drug behavior in humans
- Phase 1: Safety trials to determine safe dosage range
- Phase 2: Efficacy trials to evaluate therapeutic effects
- Phase 3: Large-scale trials to confirm efficacy and safety
- Phase 4: Post-marketing surveillance for long-term safety and efficacy
| Trial ID | Title | Phase | Status | Sponsor | Indications | Interventions | |
|---|---|---|---|---|---|---|---|
| NCT00810030 | FERINJECT for Correction of Anaemia in IBD Patients, FER-IBD-COR | PHASE3 | COMPLETED | Vifor Pharma | Inflammatory Bowel Disease|Anemia|Iron Deficiency… | DRUG: Ferric carboxymaltose|DRUG: Iron Sucrose | Details |
| NCT02517151 | Iron Supplementation in Inflammatory Bowel Disease (IBD) Patients With Chronic Fatigue | PHASE2 | UNKNOWN | Istituto Clinico Humanitas | Chronic Fatigue|Inflammatory Bowel Disease | DRUG: Ferric carboxymaltose|DRUG: Placebo | Details |
| EUCTR2022-000894-16-NL | Predicting Response to Iron Supplementation in Patients with active Inflammatory Bowel Disease_ - PRIme | PHASE4 | Not Recruiting | Leiden University Medical Center | Inflammatory Bowel Disease MedDRA version: 20.0_… | Trade Name: Feraccru Pharmaceutical Form: Capsule… | Details |
| NCT03466983 | A Randomized, Double-blinded, Comparative Trial Comparing the Incidence of Hypophosphatemia in Relation to Repeated Treatment Courses of Iron Isomaltoside and Ferric Carboxymaltose in Subjects With Iron Deficiency Anaemia Due to Inflammatory Bowel Disease | PHASE4 | Not recruiting | Pharmacosmos A/S | IBD | Drug: Iron Isomaltoside;Drug: Ferric Carboxymalto… | Details |
| EUCTR2012-005644-26-BE | Prospective Open Label study of Parenteral vs Enteral iron in Young IBD patients and Effect on physical fitness - POPEYE study | PHASE4 | Authorised | Atrium Medical Centre | Anemia and fatigue in children with Inflammatory … | Trade Name: Injectafer /ferinject. Pharmaceutical… | Details |
| EUCTR2017-002452-87-GB | A randomized, double-blinded, comparative trial comparing the incidence of hypophosphatemia in relation to repeated treatment courses of iron isomaltoside and ferric carboxymaltose in subjects with iron deficiency anaemia due to inflammatory bowel disease - hypophosphatemia following IV iron therapy in IDA due to IBD | PHASE4 | Not Recruiting | Pharmacosmos A/S | Iron deficiency anaemia due to inflammatory bowel… | Trade Name: Monofer 100mg/ml Product Name: Monofe… | Details |
| EUCTR2015-002496-26-DE | A phase 3b, randomized, controlled, multicentre study with oral ferric maltol (Feraccru) or intravenous iron (ferric carboxymaltose; FCM), for the treatment of iron deficiency anaemia in subjects with inflammatory bowel disease - ST10 versus IV iron for IDA in IBD | PHASE3 | Not Recruiting | Shield TX (UK) Ltd. | Iron deficiency anaemia with inflammatory bowel d… | Trade Name: Feraccru Product Name… | Details |
| EUCTR2011-004561-33-AT | A randomized, controlled, single-blinded, phase II study to investigate the safety and efficacy of intravenous infusions of FERINJECT versus placebo on platelet activity in patients with iron deficiency and chronic inflammatory bowel disease. The ThromboAct trial - ThromboAct | PHASE2 | Not Recruiting | Medizinische Universit Wien, Klinik f Innere Medizin III, Abteilung f Gastroenterologie und Hepatologie | iron deficiency in chronic inflammatory bowel dis… | Trade Name: Ferinject Product Name: Ferinject Pha… | Details |
| EUCTR2012-005644-26-NL | Administration of intranvenous ferric carboxymaltose to children with IBD - AFCI | Not Available | Authorised | Atrium Medical Centre | Anemia in children with Inflammatory Bowel Diseas… | Trade Name: Ferinject Product Name: ferinject Pha… | Details |
| ACTRN12613000751774 | In children with inflammatory bowel disease and iron deficiency, does intravenous iron therapy with Ferric Carboxymaltose signficantly improve cognitive function, quality of life and iron status. | PHASE4 | Not Recruiting | Gastroenterology Department, Royal Children's Hospital - Brisbane | Paediatric Inflammatory Bowel Disease;Iron defici… | In Inflammatory bowel disease patients with iron … | Details |
| NCT00882414 | A Multi-centre, Randomized, Controlled, Single-blinded, Phase II Study to Investigate the Safety and Efficacy of Intravenous Infusions of FERINJECT Versus Placebo in Patients With Thrombocytosis Secondary to Iron Deficiency and Chronic Inflammatory Bowel Disease | PHASE2 | Not recruiting | Vifor Inc. | Thrombocytosis;Iron-Deficiency Anemia | Drug: FERINJECT (Ferric carboxymaltose);Drug: Pla… | Details |
| NCT00810004 | A Multi-centre, Randomised, Prospective, Single-blinded, Controlled Study to Investigate the Efficacy and Safety of a Standardised Maintenance Dosage Regimen of Intravenous Ferric Carboxymaltose (FERINJECT) Versus Placebo in Patients With Iron Deficiency Caused by Inflammatory Bowel Disease | PHASE3 | Not recruiting | Vifor Inc. | Iron Deficiency;Inflammatory Bowel Disease | Drug: Ferinject | Details |
| EUCTR2008-002333-75-DE | A multi-centre, randomised, prospective, open-label study to investigate the efficacy and safety of a standardised correction dosage regimen of intravenous ferric carboxymaltose (FERINJECT) versus iron sucrose (VENOFER) for treatment of iron deficiency anaemia in patients with inflammatory bowel disease | Not Available | Not Recruiting | Vifor (International) Inc. | Iron deficiency anaemia in patients with inflamma… | Trade Name: FERINJECT 50 mg iron/ml solution for … | Details |
| EUCTR2008-003591-22-DE | A multi-centre, randomised, prospective, single-blinded, controlled study to investigate the efficacy and safety of a standardised maintenance dosage regimen of intravenous ferric carboxymaltose (FERINJECT) versus placebo in patients with iron deficiency caused by inflammatory bowel disease | Not Available | Not Recruiting | Vifor (International) Inc. | Iron deficiency anaemia in patients with inflamma… | Trade Name: FERINJECT 50 mg iron/ml solution for … | Details |
| NCT04587141 | Clinical Burden of Anemia in Inflammatory Bowel Disease: Therapeutic Trial | PHASE3 | UNKNOWN | Fondazione IRCCS Policlinico San Matteo di Pavia | Iron Deficiency Anemia|Inflammatory Bowel Diseases | DRUG: Sucrosomial iron|DRUG: Ferric Gluconate|DRU… | Details |
| NCT02086968 | Multicenter Randomized Open-label Controlled Study to Investigate Treatment Response of IV Injectafer vs Oral Iron to Baseline Hepcidin Levels in Patients With Iron Deficiency Anemia Secondary to Inflammatory Bowel Disease or Gastric Bypass | PHASE4 | Not recruiting | American Regent, Inc. | Iron Deficiency Anemia Secondary to IBD or Gastri… | Drug: Injectafer;Drug: Ferrous Sulfate tablets | Details |
| Disease ID | Disease Name | Definition | Category | Related Drugs | Mechanism | |
|---|---|---|---|---|---|---|
| No data available | ||||||
| Strategy ID | Therapeutic Strategy | Synonyms | Related Drugs | Mechanism | |
|---|---|---|---|---|---|
| No data available | |||||
Ferric Carboxymaltose: A Review in Iron Deficiency
PMID: 29532438
Year: 2018
Relationship Type:
Treatment
Score: 8.3
Intravenous ferric carboxymaltose (Ferinject((R)); Injectafer((R))) is a colloidal solution of nanoparticles which consist of a polynuclear iron (III…
A Swedish cost-utility analysis of ferric derisomaltose versus ferric carboxyma…
PMID: 40167340
Year: 2025
Relationship Type:
Treatment
Score: 6.5
OBJECTIVES: Iron deficiency anemia (IDA) is a common extraintestinal manifestation of inflammatory bowel disease (IBD), driven by impaired iron absor…
[Efficacy and safety of ferric carboxymaltose in patients with inflammatory bow…
PMID: 40058806
Year: 2025
Relationship Type:
Adverse Effect
Score: 6.5
Iron deficiency anemia (IDA) is a prevalent complication in patients with inflammatory bowel disease (IBD). Ferric carboxymaltose (FCM) is a new intr…
Safety and Efficacy of Ferric Carboxymaltose for Iron Deficiency Anemia in Infl…
PMID: 39835061
Year: 2024
Relationship Type:
Treatment
Score: 6.5
Ulcerative colitis and Crohn's disease, two types of inflammatory bowel disease (IBD), often cause anemia, primarily due to iron deficiency and chron…
A Cost-Utility Analysis of Ferric Derisomaltose Versus Ferric Carboxymaltose in…
PMID: 39292421
Year: 2024
Relationship Type:
Treatment
Score: 6.5
INTRODUCTION: Intravenous (IV) iron is the recommended treatment for patients with iron deficiency anemia (IDA) unresponsive to oral iron treatment, …
Cost-utility analysis of ferric derisomaltose versus ferric carboxymaltose in p…
PMID: 38391240
Year: 2024
Relationship Type:
Treatment
Score: 6.5
AIMS: Anemia is the most common extraintestinal complication of inflammatory bowel disease (IBD), with approximately half of cases caused by iron def…
Intravenous ferric carboxymaltose and ferric derisomaltose alter the intestinal…
PMID: 37671923
Year: 2023
Relationship Type:
Treatment
Score: 6.5
Iron deficiency anemia (IDA) is a leading global health concern affecting approximately 30% of the population. Treatment for IDA consists of replenis…
Ferric carboxymaltose for anemia in Crohn's disease patients at a tertiary cent…
PMID: 37214580
Year: 2023
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Although the gastrointestinal tract is the most affected by Crohn's disease (CD), the condition triggers other consequent manifestations,…
Association between iron deficit repletion with ferric carboxymaltose relative …
PMID: 37199058
Year: 2023
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND: Iron deficiency and iron deficiency anemia are common in pediatric inflammatory bowel disease and often require supplementation with iron…
Ferric Carboxymaltose Versus Ferrous Fumarate in Anemic Children with Inflammat…
PMID: 36563900
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: To determine whether intravenous (IV) or oral iron suppletion is superior in improving physical fitness in anemic children with inflammato…
Hypophosphataemia following ferric derisomaltose and ferric carboxymaltose in p…
PMID: 36343979
Year: 2023
Relationship Type:
Treatment
Score: 6.5
OBJECTIVE: Intravenous iron-a common treatment for anaemia and iron deficiency due to inflammatory bowel disease (IBD)-can cause hypophosphataemia. T…
Intravenous ferric carboxymaltose for the management of iron deficiency and iro…
PMID: 36056175
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Iron deficiency is the primary cause of anaemia worldwide and is particularly common among children and adolescents. Intravenous (IV) iron therapy is…
[A case of chronic enteropathy associated with SLCO2A1 gene diagnosed by capsul…
PMID: 35811122
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Chronic non-specific multiple ulcers of the small intestine is a disease condition postulated in Japan. It is an uncommon gastrointestinal disease th…
Ferric Carboxymaltose Improves the Quality of Life of Patients with Inflammator…
PMID: 35628914
Year: 2022
Relationship Type:
Treatment
Score: 6.5
Background: Iron deficiency (ID) without anaemia is a common comorbidity associated with inflammatory bowel disease (IBD) that has a negative impact …
Cost-effectiveness analysis of ferric carboxymaltose versus iron sucrose for th…
PMID: 35574429
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Iron deficiency anemia (IDA) is a common complication of inflammatory bowel disease (IBD) and can result in reduced quality of life and i…
Effectiveness and safety of an on-demand ferric carboxymaltose infusion strateg…
PMID: 35102111
Year: 2022
Relationship Type:
Adverse Effect
Score: 6.5
BACKGROUND: We evaluated an on-demand ferric carboxymaltose (FCM) infusion strategy in inflammatory bowel disease (IBD) patients with iron deficiency…
Severe Hypophosphatemia Following Ferric Carboxymaltose in a Patient With Infla…
PMID: 35047286
Year: 2021
Relationship Type:
Treatment
Score: 6.5
Inflammatory bowel disease is a chronic inflammatory condition that affects the large and small bowel, which includes Crohn's disease (CD) and ulcera…
Long-Term Effectiveness of Oral Ferric Maltol vs Intravenous Ferric Carboxymalt…
PMID: 33988236
Year: 2022
Relationship Type:
Treatment
Score: 6.5
BACKGROUND: Iron-deficiency anemia is common in inflammatory bowel disease, requiring oral or intravenous iron replacement therapy. Treatment with st…
Refractory hypophosphatemia following ferric carboxymaltose administration
PMID: 33715107
Year: 2021
Relationship Type:
Mechanism
Score: 6.5
Hypophosphatemia is a rare side effect of intravenous iron replacement. Urinary phosphate wasting due to increased FGF23 is the most likely mechanism…
Improved Hemoglobin Response with Ferric Carboxymaltose in Patients with Gastro…
PMID: 30056562
Year: 2018
Relationship Type:
Treatment
Score: 6.3
AIMS: To compare the efficacy and safety of intravenous (IV) ferric carboxymaltose (FCM) versus oral iron and other IV iron therapies in patients wit…